Liyong Pu

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing Medical University · ORCID：0000-0002-2119-3193

发表论文 100 篇 · 总被引 2499 次 · h-index 28

代表论文

• Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis (2025 · Cancer Immunology Research · 被引 16)
• Macrophages Atp6v0d2 regulates XBP1-mediated cholesterol metabolism to suppress metabolic dysfunction-associated steatohepatitis progression (2025 · International Immunopharmacology · 被引 6)
• Alteration characteristics and short wavelength infrared (SWIR) spectroscopy of the Huangtupo Cu-Zn VMS deposit, NW China: Implications for ore genesis and exploration (2025 · Ore Geology Reviews · 被引 2)
• Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. (2025 · Journal of Clinical Oncology · 被引 1)
• [Surgical treatment and survival analyses of intrahepatic cholangiocarcinoma]. (2025 · PubMed · 被引 1)
• Anatomy of the right portal vein and right hepatic vein for anatomical minimally invasive liver resection (2026 · iLiver)